Latest Breaking News On - Can fite biopharma - Page 5 : comparemela.com

Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients -April 03, 2024 at 07:06 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of.

Can-Fite BioPharma (CANF) Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite BioPharma, Ltd. announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80.

Can-Fite Reports 2023 Financial Results and Clinical Update

Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma .

Can Fite BioPharma : 20F FOR 2023 -March 28, 2024 at 09:47 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐.